Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study

Conditions

• Chronic Lymphocytic Leukemia
• Hematopoietic and Lymphoid System Neoplasm
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Waldenstrom Macroglobulinemia

Interventions

• OTHER: Non-Interventional Study

Sponsor

Mayo Clinic